48,836
edits
Line 76: | Line 76: | ||
==IHC== | ==IHC== | ||
*[[Neuroendocrine markers]]:<ref name=pmid36452592>{{cite journal |vauthors=Rao KR, Upadhya IB |title=A Review on Esthesioneuroblastoma |journal=Indian J Otolaryngol Head Neck Surg |volume=74 |issue=Suppl 2 |pages=1584–1590 |date=October 2022 |pmid=36452592 |pmc=9702120 |doi=10.1007/s12070-021-02726-2 |url=}}</ref> | |||
**CD56 +ve. | |||
**Synaptophysin +ve. | |||
**Chromogranin A +ve. | |||
**NSE +ve. | |||
***Lower expression of neuroendocrine markers in IDH2 mutant tumors.{{fact}} | |||
*S-100: | *S-100: | ||
**Small round cells -ve. | **Small round cells -ve. | ||
**Sustentacular cells +ve. | **Sustentacular cells +ve. | ||
***Neuronal ONB subtype is enriched for the presence of S100 sustentacular cells. | ***Neuronal ONB subtype is enriched for the presence of S100 sustentacular cells. | ||
Others: | Others: | ||
*CD45 -ve (r/o [[lymphoma]]). | *CD45 -ve (r/o [[lymphoma]]). | ||
*AE1/AE3 | *AE1/AE3 usually -ve (~1/3 are +ve<ref name=pmid36452592/>). | ||
*CAM5.2 usu. -ve -- up to 35% +ve.<ref name=Ref_WMSP41>{{Ref WMSP|41}}</ref> | *CAM5.2 usu. -ve -- up to 35% +ve.<ref name=Ref_WMSP41>{{Ref WMSP|41}}</ref> | ||
**Higher expression of cytokeratins in IDH2 mutant tumors. | **Higher expression of cytokeratins in IDH2 mutant tumors. |
edits